system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, OBJECTIVE, METHODS, METHODS. Meshes: Administration, Intravesical, Aged, Antineoplastic Combined Chemotherapy Protocols, BCG Vaccine, Carcinoma, Chemotherapy, Adjuvant, Cystectomy, Disease Progression, Disease-Free Survival, Epirubicin, Female, Humans, Interferon alpha-2, Interferon-alpha, Kaplan-Meier Estimate, Male, Neoplasm Recurrence, Local, Neoplasm Staging, Proportional Hazards Models, Prospective Studies, Recombinant Proteins, Risk Assessment, Risk Factors, Scandinavian and Nordic Countries, Time Factors, Treatment Outcome, Tumor Burden, Urinary Bladder Neoplasms.
user
Is bacillus Calmette-Guérin superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer . A prospective , randomized , Nordic study? Context: Bacillus Calmette-Guérin (BCG) instillation is regarded as the most effective bladder-sparing treatment for patients with high-grade T1 tumours and carcinoma in situ (CIS). The major problem with this therapy is the side-effects, making maintenance therapy difficult, even impossible, in a proportion of patients. Thus, alternative schedules and drugs have been proposed. To compare BCG to the combination of epirubicin and interferon-alpha2b as adjuvant therapy of T1 tumours. This is a Nordic multicenter, prospective, randomised trial in patients with primary T1 G2-G3 bladder cancer. Initial transurethral resection (TUR) was followed by a second-look resection. Patients were randomised to receive either regimen, given as induction for 6 wk followed by maintenance therapy for 2 yr. The drugs were compared with respect to time to recurrence and progression. Also, side-effects were documented.
assistant
A total of 250 patients were randomised. At the primary end point, 62% were disease free in the combination arm as opposed to 73% in the BCG arm (p=0.065). At 24 mo, there was a significant difference in favour of the BCG-treated patients (p=0.012) regarding recurrence, although there was no difference regarding progression. The subgroup analysis showed that the superiority of BCG was mainly in those with concomitant CIS. In a multivariate analysis of association with recurrence/progression status, significant variables for outcome were type of drug, tumour size, multiplicity, status at second-look resection, and grade. A corresponding analysis was performed separately in the two treatment arms. Tumour size was the only significant variable for BCG-treated patients, while multiplicity, status at second-look resection, and grade were significant for patients treated with the combination. Final Decision: yes